Tenifatecan

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameTenifatecan
Drug Alias Name特尼替康tenifatecanumSN-2310VESA-SN38
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsLung NeoplasmsPelvic NeoplasmsPancreatic Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesOncogenex
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAchieve Life Sciences Inc
Active IndicationsN/A
Inactive IndicationsLung NeoplasmsPelvic NeoplasmsPancreatic Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A